# PP-0214 — Immune Checkpoint Inhibitors
## QA Report

**QA ID:** QA-PP-0214  
**PP ID:** PP-0214  
**Version:** 1.0.0  
**QA Status:** PASS  
**Production Status:** GOLD — READY FOR INTEGRATION

---

# 1. QA Executive Status

## Final Decision

# PASS — GOLD — READY FOR INTEGRATION

PP-0214 has been reviewed against:

- locked PP-0214 Decision Batch;
- CORE_WORKING_RULES v1.7;
- FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1;
- approved Discussion Batch depth/format reference;
- supplied PP Registry;
- supplied gastric-cancer clinical Source Materials;
- required four-artifact structure.

No critical blocker was identified.

---

# 2. QA Scope

This QA evaluates:

1. Scope fidelity.
2. Clinical evidence integrity.
3. Evidence traceability.
4. Adjacent-package ownership.
5. Patient-facing quality.
6. Knowledge Graph integrity.
7. Safety boundary.
8. Cross-artifact consistency.
9. Gold-depth compliance.
10. Repository/package readiness.

---

# 3. Governance QA

## 3.1 CORE_WORKING_RULES compliance

### WR-009 — Gold Template & Source Reference Adherence

**PASS**

The artifacts preserve the approved Gold production architecture and do not intentionally compact the four-artifact system.

The Gold-depth principle is treated as a minimum standard rather than a fixed line-count requirement.

### WR-010 — Complete Population Package Delivery

**PASS**

The package contains:

- 01_CKO.md
- 02_KNOWLEDGE_PASSPORT.md
- 03_PRIMARY_EVIDENCE_PACKAGE.md
- 04_QA_REPORT.md

### WR-010A — Immediate Gold Artifact Production

**PASS**

Production occurred immediately after the Project Coordinator's explicit approval and lock.

No additional format/depth/ZIP confirmation was requested.

### WR-010B — Final Population Package Response

**PASS**

Final response contains:

- ZIP package;
- concise artifact confirmation;
- one Boundary declaration;
- standardized QA final status.

### WR-010C — Boundary Declaration

**PASS**

Boundary uses:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

Boundary is ownership-oriented and non-duplicative.

### WR-010D — User-Controlled Continuation

**PASS**

No next PP is selected or inferred.

### WR-010E — PP-Specific Source Retrieval

**PASS**

PP-0214-specific clinical sources were searched before production.

---

# 4. Gold Depth QA

## 4.1 Absolute Gold Depth Rule

**PASS**

The package was not intentionally shortened into an executive summary.

The CKO contains:

- objectives;
- scope;
- multiple clinical knowledge blocks;
- mechanism;
- agent-specific explanation;
- treatment context;
- biomarker bridges;
- landmark evidence;
- benefits;
- limitations;
- response;
- resistance;
- safety;
- patient explanation;
- misconceptions;
- patient questions;
- Knowledge Graph;
- clinical safety boundary;
- final boundary;
- revision history.

The Knowledge Passport contains:

- identity;
- classification;
- runtime usage;
- retrieval relevance;
- clinical scope;
- knowledge units;
- evidence classification;
- authoritative sources;
- governance metadata;
- Knowledge Graph;
- boundary map;
- runtime safety rules;
- version control;
- change history.

The Evidence Package contains:

- clinical question;
- scope;
- primary sources;
- evidence hierarchy;
- evidence matrix;
- landmark evidence;
- biomarker evidence;
- safety evidence;
- response evidence;
- resistance evidence;
- evidence gaps;
- out-of-scope map;
- future update triggers;
- traceability notes;
- consistency review;
- clinical claims summary.

The QA Report contains the required multi-layer governance, clinical, educational and evidence-integrity checks.

**No intentional compacting was performed.**

---

# 5. Structural QA

| Requirement | Status | Finding |
|---|---|---|
| Four artifacts present | PASS | Complete |
| CKO structure | PASS | Complete |
| KP structure | PASS | Complete |
| Evidence Package structure | PASS | Complete |
| QA structure | PASS | Complete |
| Semantic versioning | PASS | 1.0.0 |
| Stable naming | PASS | Standard filenames |
| PP ID consistency | PASS | PP-0214 throughout |
| Title consistency | PASS | Immune Checkpoint Inhibitors |
| Gold status | PASS | Consistent |

---

# 6. Clinical QA

## 6.1 Mechanism

**PASS**

PD-1/PD-L1 and CTLA-4 mechanisms are described at conceptual rather than laboratory level.

The explanation is consistent with ACS and NCCN source framing.

---

## 6.2 Agent identity

**PASS**

The package identifies:

- nivolumab;
- pembrolizumab;
- tislelizumab;
- durvalumab;
- dostarlimab;
- ipilimumab in selected dual-checkpoint context.

The supplied ACS and NCI materials support the named agents.

---

## 6.3 Current guideline positioning

**PASS**

Current NCCN v2.2026 is treated as the disease-specific authority.

Examples include:

- nivolumab + chemotherapy;
- pembrolizumab + chemotherapy;
- tislelizumab + chemotherapy;
- pembrolizumab + trastuzumab + chemotherapy;
- MSI-H/dMMR checkpoint strategies;
- perioperative checkpoint strategies.

---

## 6.4 CheckMate-649

**PASS**

The package preserves the key distinction between:

- broad-population nivolumab + chemotherapy evidence;
- MSI-H subgroup benefit;
- dual-checkpoint results that were not broadly positive but showed a stronger MSI-H signal.

This prevents overgeneralization.

---

## 6.5 KEYNOTE-859

**PASS**

The package preserves:

- HER2-negative advanced population;
- pembrolizumab + chemotherapy;
- PD-L1 CPS subgroup context;
- major OS/PFS/ORR figures;
- context-dependent interpretation.

---

## 6.6 RATIONALE-305

**PASS**

The package preserves:

- tislelizumab + chemotherapy;
- all-randomized evidence;
- PD-L1 TAP subgroup;
- distinction between TAP and CPS.

---

## 6.7 KEYNOTE-811

**PASS**

The package preserves:

- HER2-positive context;
- pembrolizumab + trastuzumab + chemotherapy;
- PD-L1 CPS ≥1 subgroup relevance;
- PFS and ORR evidence;
- boundary to PP-0210.

---

## 6.8 MATTERHORN

**PASS**

The package correctly treats MATTERHORN as perioperative evidence and does not absorb detailed FLOT management.

---

## 6.9 MSI-H/dMMR

**PASS**

The package correctly presents MSI-H/dMMR as a major checkpoint-treatment context.

It does not absorb:

- MSI testing methodology;
- MMR IHC workflow;
- hereditary assessment;
- detailed MSI biology.

---

## 6.10 PD-L1

**PASS**

PD-L1 is treated as a treatment-context bridge.

The package does not reproduce:

- CPS calculation;
- TAP calculation;
- IHC laboratory methodology.

---

## 6.11 TMB-H

**PASS WITH EXPLICIT CAUTION**

The package preserves the NCCN limitation that no gastroesophageal cancer patients were included in the relevant KEYNOTE-158 TMB analysis.

No unsupported gastric-specific certainty was introduced.

---

# 7. Safety QA

## 7.1 Immune-related adverse events

**PASS**

The package explains:

- why irAEs occur;
- important organ systems;
- common symptoms;
- serious symptoms;
- need for prompt reporting.

## 7.2 Detailed management boundary

**PASS**

No:

- steroid dosing;
- CTCAE grading;
- immunosuppression algorithm;
- rechallenge algorithm;

was introduced.

Detailed management is delegated to PP-0231.

## 7.3 Infusion reactions

**PASS**

Patient-facing awareness is included without creating an infusion-management protocol.

---

# 8. Response / Resistance QA

## Response

**PASS**

The package includes:

- durable response;
- pseudoprogression;
- mixed response;
- hyperprogression.

It does not attempt formal RECIST/iRECIST assessment.

## Resistance

**PASS**

Primary and acquired resistance are included conceptually.

Detailed molecular resistance management is excluded.

---

# 9. Adjacent PP Overlap QA

## PP-0213 — Immunotherapy in Gastric Cancer

**PASS**

PP-0213 owns the umbrella immunotherapy concept.

PP-0214 owns the checkpoint-inhibitor class.

No substantive duplication is intentionally created.

---

## PP-0215 — MSI-H/dMMR Gastric Cancer and Immunotherapy

**PASS**

PP-0214 consumes MSI-H/dMMR as a treatment-context bridge.

PP-0215 owns the deeper biomarker-specific clinical package.

---

## PP-0216 — PD-L1-guided Immunotherapy

**PASS**

PP-0214 explains why PD-L1 matters.

PP-0216 owns detailed PD-L1-guided treatment interpretation.

---

## PP-0182 — MSI/MMR Testing

**PASS**

Testing methodology is excluded.

---

## PP-0183 — PD-L1 Testing

**PASS**

Testing/scoring methodology is excluded.

---

## PP-0210 — HER2-targeted Therapy

**PASS**

KEYNOTE-811 is used only to establish the checkpoint-inhibitor role in the combination.

Detailed HER2 treatment is delegated.

---

## PP-0231 — Treatment-related Toxicity and Supportive Care

**PASS**

PP-0214 contains safety awareness only.

Detailed management is delegated.

---

## PP-0217–0219 — Response Assessment

**PASS**

Unconventional response concepts are included, but formal response assessment is delegated.

---

# 10. Knowledge Graph QA

## Prerequisite linkage

**PASS**

The package links to foundational immunotherapy and biomarker packages.

## Related linkage

**PASS**

The package links to adjacent targeted-treatment and biomarker packages.

## Downstream linkage

**PASS**

The package links to:

- PP-0215;
- PP-0216;
- PP-0217;
- PP-0218;
- PP-0219;
- PP-0231.

No unsupported next PP was invented.

---

# 11. Patient-facing QA

## Plain language

**PASS**

Technical terms are introduced before detailed use.

## Neutrality

**PASS**

No sensational or promotional language.

## Evidence calibration

**PASS**

The package distinguishes:

- established;
- context-dependent;
- evidence-limited.

## Individualized-treatment avoidance

**PASS**

No individualized treatment recommendation is presented.

## Safety messaging

**PASS**

Prompt reporting of new symptoms is emphasized.

---

# 12. Evidence Traceability QA

## Source-first

**PASS**

Project Source Files were searched before production.

## Source hierarchy

**PASS**

NCCN v2.2026 is primary for current gastric-cancer treatment positioning.

## Supporting sources

**PASS**

NCI, ACS and ESMO-ASCO are used for their appropriate roles.

## No silent source substitution

**PASS**

External web knowledge was not used to replace the supplied project clinical evidence base.

---

# 13. Terminology QA

Terminology is standardized around:

- immune checkpoint inhibitor;
- PD-1;
- PD-L1;
- CTLA-4;
- MSI-H;
- dMMR;
- PD-L1 CPS;
- PD-L1 TAP;
- HER2-positive / HER2-negative;
- perioperative;
- advanced/metastatic;
- immune-related adverse event.

CPS and TAP are explicitly kept conceptually distinct.

---

# 14. Common Overclaim QA

| Potential overclaim | Status |
|---|---|
| “ICI works for everyone” | Prevented |
| “PD-L1 guarantees response” | Prevented |
| “MSI-H guarantees response” | Prevented |
| “TMB-H is strongly validated in gastric cancer” | Prevented |
| “All ICIs are interchangeable” | Prevented |
| “Nivolumab + ipilimumab is universally superior” | Prevented |
| “Any progression is pseudoprogression” | Prevented |
| “ICI toxicity is always mild” | Prevented |
| “One ICI is universally best” | Prevented |
| “Biomarker result alone determines treatment” | Prevented |

---

# 15. Internal Consistency QA

## CKO ↔ KP

**PASS**

Scope and Knowledge Units are aligned.

## CKO ↔ Evidence Package

**PASS**

Clinical claims in CKO are represented in the Evidence Package.

## CKO ↔ QA

**PASS**

QA findings correspond to actual CKO content.

## KP ↔ Evidence Package

**PASS**

Evidence classifications and source hierarchy are consistent.

## Boundary ↔ Scope

**PASS**

Boundary categories reflect the approved locked Decision Batch.

---

# 16. Repository QA

Required repository structure:

```text
PP-0214_Immune_Checkpoint_Inhibitors_GOLD_v1.0.0/
├── 01_CKO.md
├── 02_KNOWLEDGE_PASSPORT.md
├── 03_PRIMARY_EVIDENCE_PACKAGE.md
└── 04_QA_REPORT.md
```

**PASS**

All required artifacts are present.

---

# 17. Package Integrity QA

## Filename

Required elements:

- PP number;
- full title;
- GOLD;
- version.

**PASS**

`PP-0214_Immune_Checkpoint_Inhibitors_GOLD_v1.0.0.zip`

## Artifact filenames

**PASS**

- 01_CKO.md
- 02_KNOWLEDGE_PASSPORT.md
- 03_PRIMARY_EVIDENCE_PACKAGE.md
- 04_QA_REPORT.md

## Artifact count

**PASS — 4/4**

## Cross-file PP ID

**PASS — PP-0214**

## Cross-file title

**PASS — Immune Checkpoint Inhibitors**

## Cross-file version

**PASS — 1.0.0**

---

# 18. Gold Production Checklist

| Gold requirement | Result |
|---|---|
| Approved Decision Batch respected | PASS |
| Source-first verification | PASS |
| PP-specific source search | PASS |
| Governance search | PASS |
| Gold Discussion reference reviewed | PASS |
| Adjacent PP check | PASS |
| Absolute Gold Depth | PASS |
| CKO depth | PASS |
| KP depth | PASS |
| Evidence Package depth | PASS |
| QA depth | PASS |
| Knowledge Graph | PASS |
| Evidence traceability | PASS |
| Patient-facing depth | PASS |
| Boundary ownership | PASS |
| Safety boundary | PASS |
| Four artifacts | PASS |
| ZIP package | PASS |
| Versioning | PASS |
| Repository readiness | PASS |

---

# 19. Known Limitations

The following are intentional limitations, not QA failures:

1. Current clinical treatment selection requires the current guideline and patient-specific clinical context.
2. Cross-trial comparisons are not equivalent to head-to-head comparisons.
3. Biomarker evidence varies by assay and population.
4. Detailed toxicity management is outside this PP.
5. Formal response assessment is outside this PP.
6. Detailed resistance mechanisms are outside this PP.
7. Regulatory approvals may change independently of guideline wording.

---

# 20. QA Final Assessment

## Content QA

**PASS**

Scope is complete for the approved PP question.

## Clinical QA

**PASS**

No material guideline conflict or unsupported clinical certainty identified within the approved scope.

## Educational QA

**PASS**

Patient-facing explanation, terminology and logical flow are appropriate for a high-complexity treatment-class package.

## Governance QA

**PASS**

Evidence traceability, versioning, Knowledge Graph linkage, artifact structure and repository readiness are compliant.

---

# 21. Final QA Status

# **PASS — GOLD — READY FOR INTEGRATION**

---

# 22. Revision History

| Version | Date | Summary |
|---|---|---|
| 1.0.0 | 2026-08-09 | Initial Gold QA Report following PP-0214 Decision Batch approval and lock. |
